5-lipoxygenase regulates malignant mesothelial cell survival: involvement of vascular endothelial growth factor
- PMID: 11689458
- DOI: 10.1096/fj.01-0150com
5-lipoxygenase regulates malignant mesothelial cell survival: involvement of vascular endothelial growth factor
Abstract
Evidence indicates that lipoxygenases (LO) may play a role in cancer cell survival. We show that human malignant pleural mesothelial (MM) cells, but not normal mesothelial (NM) cells, express a catalytically active 5-LO. Pharmacological or genetic inhibition of MM cell 5-LO determined nucleosome formation and induced a DNA fragmentation pattern typical of apoptosis. This was completely reversed by exogenously added 5(S)-HETE but not by 12(S)-, 15(S)-HETE, or leukotriene (LT)B4. A 5-LO antisense oligonucleotide potently and time-dependently reduced vascular endothelial growth factor (VEGF) mRNA and constitutive VEGF accumulation in the conditioned media of MM cells. When NM cells were transfected with a 5-LO cDNA, basal and arachidonic acid-induced VEGF formation increased consistently by 6- and 12-fold, respectively. This was associated with a significant increase in DNA synthesis that was counteracted by a specific anti-VEGF antibody. Arachidonic acid and 5(S)-HETE also potently stimulated the activity of a VEGF promoter construct. Thus, 5-LO is a key regulator of MM cell proliferation and survival via a VEGF-related circuit.
Similar articles
-
Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma.J Pathol. 2001 Apr;193(4):468-75. doi: 10.1002/path.824. J Pathol. 2001. PMID: 11276005
-
Aplidine, a new anticancer agent of marine origin, inhibits vascular endothelial growth factor (VEGF) secretion and blocks VEGF-VEGFR-1 (flt-1) autocrine loop in human leukemia cells MOLT-4.Leukemia. 2003 Jan;17(1):52-9. doi: 10.1038/sj.leu.2402788. Leukemia. 2003. PMID: 12529660
-
The growth inhibition of hepatoma by gene transfer of antisense vascular endothelial growth factor.J Gene Med. 2000 Jul-Aug;2(4):289-96. doi: 10.1002/1521-2254(200007/08)2:4<289::AID-JGM116>3.0.CO;2-1. J Gene Med. 2000. PMID: 10953920
-
Role of lipoxygenases in breast cancer.Front Biosci. 1998 Jun 8;3:E81-8. doi: 10.2741/a369. Front Biosci. 1998. PMID: 9616130 Review.
-
Genetic variations in the 5-lipoxygenase core promoter. Description and functional implications.Am J Respir Crit Care Med. 2000 Feb;161(2 Pt 2):S77-80. doi: 10.1164/ajrccm.161.supplement_1.ltta-16. Am J Respir Crit Care Med. 2000. PMID: 10673232 Review. No abstract available.
Cited by
-
The eicosanoid cascade: possible role in gliomas and meningiomas.J Clin Pathol. 2004 Jan;57(1):6-13. doi: 10.1136/jcp.57.1.6. J Clin Pathol. 2004. PMID: 14693827 Free PMC article. Review.
-
The Investigation of Lipoxygenases as Therapeutic Targets in Malignant Pleural Mesothelioma.Pathol Oncol Res. 2020 Apr;26(2):985-995. doi: 10.1007/s12253-019-00652-x. Epub 2019 Apr 2. Pathol Oncol Res. 2020. PMID: 30941737 Free PMC article.
-
Cancer-produced metabolites of 5-lipoxygenase induce tumor-evoked regulatory B cells via peroxisome proliferator-activated receptor α.J Immunol. 2013 Mar 15;190(6):2575-84. doi: 10.4049/jimmunol.1201920. Epub 2013 Feb 13. J Immunol. 2013. PMID: 23408836 Free PMC article.
-
Serum vascular endothelial growth factor and COX-2/5-LOX inhibition in advanced non-small cell lung cancer: Cancer and Leukemia Group B 150304.J Thorac Oncol. 2011 Nov;6(11):1902-6. doi: 10.1097/JTO.0b013e31822a7383. J Thorac Oncol. 2011. PMID: 21964530 Free PMC article. Clinical Trial.
-
Cross-Talk between Cancer Cells and the Tumour Microenvironment: The Role of the 5-Lipoxygenase Pathway.Int J Mol Sci. 2017 Jan 24;18(2):236. doi: 10.3390/ijms18020236. Int J Mol Sci. 2017. PMID: 28125014 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical